Acquired C1 inhibitor deficiency associated with lymphoproliferative disorders is sometimes asymptomatic. Diagnosis could be delay in spite of clinical manifestations. Deficit correction is not constant after lymphoproliferative disorders treatment.
Latagliata R, Niscola P, Fianchi L, et al. Pulmonary infections in patients with myelodysplastic syndromes receiving azacytidine treatment. Blood 2016 ; 128 : 5544.[6] Pomares H, Arnan M, S anchez-Ortega I, Sureda A, Duarte RF. Invasive fungal infections in AML/ MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses 2016 ; 59 : 516-9.[7] Trubiano JA, Dickinson M, Thursky KA, et al. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.